CDDO-ethyl amide

RTA 405 (CDDO-EA) is an orally bioavailable synthetic oleanane triterpenoid developed by Reata Pharmaceuticals. It acts primarily as a potent activator of the Nrf2 antioxidant pathway and also directly inhibits IKKβ, thereby reducing NF-κB activity. These mechanisms confer antioxidative and anti-inflammatory properties to the compound. RTA 405 has demonstrated neuroprotective effects in preclinical models of neurodegenerative diseases such as Huntington’s disease and ALS, as well as efficacy in animal models of chronic kidney disease, diabetes, liver fibrosis, and cancer. The drug can cross the blood-brain barrier in animals but has not been tested in humans or entered clinical trials[1][2][3][4][6].

Other names

2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate-ethyl amide